The first partnership between the CVHLA and the CRS in 2018 created a grant that was won by Dr. Najafabadi (see above for details)
These prizes have attracted very high quality VHL related proposals that the CRS has also funded. Click here for more details.
More about the Cancer Research Society (CRS)
In 2017 the Cancer Research Society has funded the following projects that are related to the VHL gene and/or ccRCC:
Dr. Ryan Russell, University of Ottawa: Characterization of VHL-mediated RB regulation in renal cancer
Dr. Stefan Taubert, The University of British Columbia (UBC): Exploring Mediator-dependent stress resistance as a new target (a protein acting downstream of VHL, in the same molecular pathway)
Dr. Yasser Riazalhosseini, McGill University: KDM5C mutations as determinants of sex-dependent therapy in renal cell carcinoma
Dr. Damu Tang, McMaster University: Characterization of CYB5D2-mediated suppression of clear cell renal cell carcinoma (ccRCC)
Three grants on VHL were funded by the Cancer Research Society in the past years:
Sandra Turcotte, U of Moncton (2012-2014): The late-stage of autophagy: A role for the tumor suppressor gene von Hippel-Lindau in lysosomal degradation
Amin Pause, McGill University (2006-2008): The von Hippel-Lindau (VHL) protein suppresses angiogenesis by maintaining extracellular matrix integrity
Stephen Lee, University of Ottawa (2004-2006): Dissecting the oncogenic pathway of VHL loss kidney cancer
Our CVHLA goal is to apply a very large percentage of our donations directly to funding Research Projects.
Please click here for the final report by Dr. Najafabadi
Please click here for the interum report by Dr. Turcott
Click here to link to The National Health Institute Research Database on von Hippel-Lindau Disease